A double-blind randomized discontinuation phase-ii study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: Eastern cooperative oncology group study E2501

Journal of Thoracic Oncology

Volumn 7, Issue 10, 2012, Pages 1574-1582

  Wakelee, Heather A ^a   Lee, Ju Whei ^b   Hanna, Nasser H ^c   Traynor, Anne M ^d   Carbone, David P ^e   Schiller, Joan H ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Non small cell lung cancer; Randomized discontinuation trial; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOATING; BONE PAIN; BRAIN ISCHEMIA; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEHYDRATION; DESQUAMATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMOLYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIMB PAIN; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBUS; TREATMENT RESPONSE; WEAKNESS; WEIGHT REDUCTION;

EID: 84866625336     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826149ba     Document Type: Article

References (31)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
3. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. (Pubitemid 39331023)
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22. (Pubitemid 37328883)
5. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-334. (Pubitemid 43338212)
6. Wilhelm S Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-2257. (Pubitemid 35189898)
7. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-225. (Pubitemid 32947644)
8. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480. (Pubitemid 41060823)
9. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972. (Pubitemid 46202316)
10. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-437. (Pubitemid 46698720)
11. Escudier B, Eisen T, Stadler WM, et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
12. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512. (Pubitemid 46630627)
13. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300. (Pubitemid 46630787)
14. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 1993;46:959-971. (Pubitemid 23258894)
15. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
16. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074. (Pubitemid 32717538)
17. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000. (Pubitemid 35424092)
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
19. Yamamoto N, Nishiwaki Y, Negoro S, et al. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15- 32) in advanced non-small cell lung cancer patients. J Thorac Oncol 2010;5:1042-1047.
20. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
21. Lind JS, Dingemans AM, Groen HJ, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:3078-3087.
22. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-4280.
23. Myung HJ, Jeong SH, Kim JW, et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver 2010;4:543-546.
24. Ide S, Soda H, Hakariya T, et al. Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer 2010;67:248-250.
25. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 2010;5:719-720.
26. Kelly RJ, Rajan A, Force J, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17:1190-1199.
27. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-1842.
28. Gatzemeier U, Eisen T, Santoro A, et al. Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC); Phase III NSCLC Research Experience Utilizing Sorafenib (NEXUS) trial. Ann Oncol 2010;21 (Suppl 8):viii7(abstr LBA 16).
29. Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582-2589.
30. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011;22:1528-1534.
31. Dy GK, Hillman SL, Rowland KM Jr, et al.; North Central Cancer Treatment Group Study N0326. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010;116:5686-5693.